
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline
Funds will advance two novel drug candidates, SP-624 for major depressive disorder moving into late-stage development, and RABI-767 for the treatment of severe acute pancreatitis entering Phase 2 SP-624 is a first-in-class treatment activating SIRT6 for the treatment of major depression and other neuropsychiatric disorders MORRISVILLE, N.C.–(BUSINESS WIRE)–Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed … Continue reading ArrivoBio Raises $45M in Series B Financing to Advance Pipeline